NRIX
NASDAQ · Biotechnology
Nurix Therapeutics Inc
$15.22
+0.78 (+5.40%)
Open$14.68
Previous Close$14.44
Day High$15.25
Day Low$14.67
52W High$22.50
52W Low$8.18
Volume—
Avg Volume786.1K
Market Cap1.62B
P/E Ratio—
EPS$-3.04
SectorBiotechnology
Analyst Ratings
Strong Buy
23 analysts
Price Target
+375.0% upside
Current
$15.22
$15.22
Target
$72.29
$72.29
$45.76
$72.29 avg
$82.91
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 100.68M | 77.72M | 234.23M |
| Net Income | -317,027,614 | -220,260,037 | -24,379,697 |
| Profit Margin | -314.9% | -299.2% | -10.4% |
| EBITDA | -331,978,218 | -243,460,944 | -31,389,191 |
| Free Cash Flow | — | — | -25,443,977 |
| Rev Growth | +29.5% | +29.5% | +16.3% |
| Debt/Equity | — | — | 0.64 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $207.18 | +0.96% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.93 | +1.58% | 24.4 | 188.06B |
| GILD | Gilead Sciences Inc | $138.26 | +0.11% | 20.0 | 170.34B |
| VRTX | Vertex Pharmaceuticals Inc | $454.97 | +1.42% | 29.2 | 115.53B |
| REGN | Regeneron Pharmaceuticals | $749.47 | +1.05% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.70 | +6.70% | 139.7 | 43.84B |